Semaglutide vs Tirzepatide: Which GLP-1 Medication Is Right for You?

Semaglutide and tirzepatide work differently at the molecular level, which explains some of the differences in their clinical effects. Semaglutide (GLP-1 receptor agonist): Semaglutide mimics a single hormone — glucagon-like peptide-1 (GLP-1). This hormone is naturally produced in the gut after eating and signals to your brain that you are full. Semaglutide binds to GLP-1 receptors throughout the body, including the brain (reducing appetite), stomach (slowing digestion), and pancreas (boosting insulin secretion and reducing glucagon). It is administered as a once-weekly subcutaneous injection. Tirzepatide (dual GLP-1/GIP receptor agonist): Tirzepatide is a first-in-class dual agonist that mimics two hormones: GLP-1 (same as semaglutide) AND glucose-dependent insulinotropic polypeptide (GIP). GIP is another incretin hormone that enhances insulin secretion and may have unique effects on fat metabolism and energy expenditure. The dual mechanism is believed to be the reason tirzepatide produces greater weight loss than GLP-1-only medications. [1] Key takeaway: Both medications reduce appetite and slow gastric emptying. Tirzepatide has an additional mechanism (GIP activation) that may contribute to its superior weight loss results.

The clinical trial data is clear: tirzepatide produces more weight loss than semaglutide on average. STEP-1 trial (semaglutide 2.4 mg, 68 weeks): - Average weight loss: 14.9% of body weight (~33 lbs for a 220-lb person) - Proportion losing ≥5%: 84% - Proportion losing ≥10%: 70% - Proportion losing ≥20%: 24% SURMOUNT-1 trial (tirzepatide 15 mg, 72 weeks): - Average weight loss: 22.5% of body weight (~50 lbs for a 220-lb person) - Proportion losing ≥5%: 91% - Proportion losing ≥10%: 81% - Proportion losing ≥20%: 41% SURPASS-2 (direct comparison in type 2 diabetes patients): This head-to-head trial compared tirzepatide (5, 10, 15 mg) to semaglutide (1 mg) in patients with type 2 diabetes. Tirzepatide 15 mg produced significantly greater weight loss (12.4 kg vs. 8.3 kg) and better HbA1c reduction. Real-world data: Electronic health record analyses from 2024-2025 show similar patterns — tirzepatide patients lose approximately 50% more weight than semaglutide patients at comparable time points. However, individual results vary widely, and some patients respond better to semaglutide. Non-scale outcomes comparison: Beyond weight, both medications show important health improvements, but tirzepatide has a slight edge in several metabolic markers. In the SURMOUNT-1 trial, tirzepatide reduced waist circumference by an average of 19.4 cm (7.6 inches) compared to semaglutide's 14.3 cm in the STEP-1 trial. Blood pressure reductions were comparable (6-7 mmHg systolic for both). HbA1c improvements favored tirzepatide in head-to-head comparisons (1.5-2.0% reduction vs. 1.0-1.4% for semaglutide). Triglyceride reductions were also greater with tirzepatide (20-25% vs. 12-15%). These metabolic differences may be clinically meaningful for patients with type 2 diabetes, high triglycerides, or significant abdominal obesity. [2] See our semaglutide results timeline and tirzepatide before and after pages for detailed patient outcome data.

Both medications share similar side effect profiles (primarily gastrointestinal), but tirzepatide appears to cause fewer GI issues at therapeutic doses. Common side effects comparison: | Side Effect | Semaglutide | Tirzepatide | |---|---|---| | Nausea | 44% | 24% | | Vomiting | 25% | 12% | | Diarrhea | 30% | 18% | | Constipation | 24% | 17% | | Abdominal pain | 20% | 14% | | Fatigue | 11% | 8% | Serious but rare side effects (both medications): - Pancreatitis (approximately 0.1-0.3%) - Gallbladder disease (2-4%) - Hypoglycemia (when combined with other diabetes medications) - Thyroid C-cell tumors (seen in rodent studies, not confirmed in humans) - Kidney injury (usually secondary to dehydration from vomiting) Notable differences: Semaglutide has a higher rate of injection site reactions (6% vs. 3%). Tirzepatide has been associated with slightly higher rates of gallbladder disease in clinical trials. Both medications carry the same FDA boxed warning about thyroid C-cell tumors based on rodent data. For most patients, side effects are manageable and improve over the first 2-3 months of treatment. The titration schedule (starting at a low dose and gradually increasing) is designed to minimize GI side effects. [3]

Cost is often the deciding factor for patients choosing between semaglutide and tirzepatide. Branded medication (retail): - Wegovy (semaglutide 2.4 mg): $1,212-$1,587/month - Zepbound (tirzepatide 15 mg): $1,229-$1,612/month Branded prices are essentially equivalent. Neither has a clear cost advantage at retail. Compound medication (telehealth): Compound semaglutide is generally cheaper than compound tirzepatide: - Compound semaglutide: $85-$399/month (Mochi $85, Hims $199, Henry Meds $249) - Compound tirzepatide: $199-$499/month (Hims $299, Henry Meds $349, Numinous $399) Insurance coverage: Both medications face similar coverage barriers. Approximately 60-70% of commercial plans cover one or both. Some plans prefer one over the other on their formulary. If your plan covers both, the copay is typically similar ($25-$100/month). Value analysis: Tirzepatide produces more weight loss per dollar spent on compound medication. At compound prices, semaglutide from Mochi ($85/month) is the cheapest option, while tirzepatide ($199+/month) costs more but may deliver faster, greater weight loss. The cost-per-pound-lost is comparable between the two. [4] See our semaglutide cost guide and tirzepatide cost guide for detailed pricing breakdowns.

Both medications are once-weekly subcutaneous injections, but their dosing schedules differ. Semaglutide (Wegovy) titration: - Month 1: 0.25 mg/week (starter dose) - Month 2: 0.5 mg/week - Month 3: 1 mg/week - Month 4: 1.7 mg/week - Month 5+: 2.4 mg/week (target maintenance) Tirzepatide (Zepbound) titration: - Month 1: 2.5 mg/week (starter dose) - Month 2: 5 mg/week - Month 3: 7.5 mg/week - Month 4: 10 mg/week - Month 5+: 12.5 or 15 mg/week (target maintenance) Key differences: - Semaglutide reaches target dose at month 5, tirzepatide at month 5+ - Wegovy comes in pre-filled pens; compound versions use vials and insulin syringes - Both can be injected in the abdomen, thigh, or upper arm - Both should be injected on the same day each week, at any time of day - Both can be stored in the refrigerator (or at room temperature for up to 28 days for Wegovy pens) Flexibility: Some providers allow patients to stay at lower doses if they are achieving good results with minimal side effects. This "lowest effective dose" approach can reduce side effects and, for compound patients, reduce costs. [5]

The decision between semaglutide and tirzepatide depends on several personal factors. Here is a practical framework: Choose semaglutide if: - Cost is a primary concern (compound semaglutide starts at $85/month) - You want the medication with the most long-term safety data (semaglutide has been used since 2017) - Your insurance covers Wegovy but not Zepbound - You prefer a slightly simpler titration schedule - You have a history of gallbladder issues (tirzepatide has slightly higher gallbladder risk) Choose tirzepatide if: - Maximum weight loss is your priority - You are concerned about GI side effects (tirzepatide has lower nausea rates) - You have type 2 diabetes and want better glucose control - Your insurance covers Zepbound but not Wegovy - You have tried semaglutide and did not achieve desired results The bottom line: Both medications are highly effective. Tirzepatide has a slight edge in efficacy and tolerability, while semaglutide has more long-term data and lower compound costs. Many providers start with semaglutide due to cost and familiarity, then switch to tirzepatide if results are inadequate. The best choice is the one you can afford and stick with consistently. [6] Use our price comparison tool to find the most affordable option for your situation, or read our telehealth provider guide to find a prescriber.

Understanding the long-term safety profile of these medications is essential for patients who may be on them for years. Both semaglutide and tirzepatide have accumulated significant safety data, though semaglutide has a longer track record. Semaglutide — years of data: Semaglutide has been on the market since 2017 (originally as Ozempic for type 2 diabetes) and has been used by millions of patients worldwide. The SUSTAIN trial program (diabetes), STEP trial program (obesity), and SELECT cardiovascular trial provide extensive safety data spanning 2-5 years of continuous use. The SELECT trial was particularly important: it demonstrated that semaglutide reduces major adverse cardiovascular events (MACE) by 20% in patients with established cardiovascular disease and obesity. This cardiovascular benefit — the first proven for any GLP-1 medication in a dedicated outcomes trial — has led many cardiologists to recommend semaglutide for patients with both obesity and heart disease. Kidney outcomes data from the FLOW trial also showed that semaglutide reduces the risk of kidney failure and significant kidney function decline in patients with type 2 diabetes and chronic kidney disease. Tirzepatide — growing but newer data: Tirzepatide has been available since 2022 (as Mounjaro for type 2 diabetes) and has accumulated approximately 4 years of clinical experience. The SURPASS and SURMOUNT trial programs have enrolled over 15,000 patients cumulatively, with 2-year extension data showing sustained weight loss and acceptable safety. The ongoing SURPASS-CVOT trial (cardiovascular outcomes) is expected to report results in 2027 and will determine whether tirzepatide shares semaglutide's cardiovascular benefit. In the meantime, early signals from metabolic marker improvements (blood pressure, lipids, inflammation markers) are encouraging but not yet confirmed in a dedicated outcomes trial. Weight regain after discontinuation: Both medications show similar patterns of weight regain upon discontinuation. Extension data from the STEP and SURMOUNT trials shows that patients who stop treatment regain approximately 60-70% of their lost weight within one year. This has led most obesity medicine specialists to recommend long-term or indefinite use, similar to how we approach blood pressure or cholesterol medications. The weight regain data underscores the importance of viewing GLP-1 medications as a chronic treatment for a chronic condition, not a temporary intervention. Rare but serious long-term risks: Both medications carry the same FDA boxed warning about thyroid C-cell tumors based on rodent studies. After millions of patient-years of use, this risk has not been observed in humans, but monitoring continues. Post-marketing surveillance has identified rare cases of pancreatitis, gallbladder disease, and diabetic retinopathy worsening in patients with pre-existing eye disease. The overall safety profile of both medications is considered favorable compared to the health risks of untreated obesity.